Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

The effect of sarcopenia on the clinical outcomes of patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is unclear. The aim of this study was to evaluate the effect and survival of patients with malignancies and sarcopenia receiving ICIs. We systematically searched relat...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-08, Vol.11, p.726257-726257
Main Authors: Li, Shuluan, Wang, Tianyu, Tong, Gangling, Li, Xiaoyu, You, Danhui, Cong, Minghua
Format: Article
Language:English
Subjects:
immunotherapy
malignancies
meta-analysis
Oncology
predictive factor
sarcopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3
cites cdi_FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3
container_end_page 726257
container_issue
container_start_page 726257
container_title Frontiers in oncology
container_volume 11
creator Li, Shuluan
Wang, Tianyu
Tong, Gangling
Li, Xiaoyu
You, Danhui
Cong, Minghua
description The effect of sarcopenia on the clinical outcomes of patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is unclear. The aim of this study was to evaluate the effect and survival of patients with malignancies and sarcopenia receiving ICIs. We systematically searched related studies in PubMed, Embase, and Cochrane Library up to March 2021 according to the inclusion and exclusion criteria. Information pertaining to the hazard ratio (HR) corresponding to 95% confidence interval (CI) of overall survival (OS) and progression-free survival (PFS) as determined by univariate and multivariate analyses; the odds ratio (OR) corresponding to the 95% CI of the disease control rate (DCR) and objective response rate (ORR); and immune-related adverse events (irAEs) was collected and analyzed using the RevMan 5.4 software. Study heterogeneity and sensitivity were also assessed. A total of 19 studies were finalized that included 1763patients with lung, gastrointestinal, and head and neck cancers as well as those with melanoma, renal cell carcinoma, urothelial carcinoma, pancreatic cancer, and soft tissue sarcoma. According to univariate and multivariate analyses, patients with sarcopenia at pre-immunotherapy had poorer PFS and OS than those without. HRs and the corresponding 95% CI of PFS were 1.91(1.55-2.34, p
doi_str_mv 10.3389/fonc.2021.726257
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_43bf097d4080441aa9a6aeeea9f03ac4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_43bf097d4080441aa9a6aeeea9f03ac4</doaj_id><sourcerecordid>2572211717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3</originalsourceid><addsrcrecordid>eNpVkktv1DAQgCMEolXpnRPykUu2fm2S5YC0WgFdqVURLYKbNXHGuy6JndpO0f4Q_i9etlStL37MzDcj-SuKt4zOhGgWZ8Y7PeOUs1nNKz6vXxTHnAtZLqT4-fLJ-ag4jfGW5lXNKaPidXEk5JyJmsrj4s_X4DfOx2Q1WQ8j6ES8IdcQtB_RWSDekVVvndXQk6spaT9gJNaRS-jtxoHTNt9vAkLCjvywaZsxw-SQrLaof43eukTWbmtbm3yIH8iSXO9iwgH2Hb_hvcXfBFxHLjFBuXTQ76KNb4pXBvqIpw_7SfH986eb1Xl5cfVlvVpelFpWPJWSdwg1b7RspJEtdnU7r0SlBXbYGAFVwxFojlVoQDSmoYaB6JgxvBMN0-KkWB-4nYdbNQY7QNgpD1b9e_BhoyDkQXtUUrSGLupO0oZKyQAWUAEiwsJQAVpm1scDa5zaATuNLgXon0GfR5zdqo2_V43kdV2xDHj_AAj-bsKY1GCjxr4Hh36KKn8x54zVrM6p9JCqg48xoHlsw6jay6H2cqi9HOogRy5593S8x4L_Koi_IDu6IQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572211717</pqid></control><display><type>article</type><title>Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis</title><source>PubMed Central (Open Access)</source><creator>Li, Shuluan ; Wang, Tianyu ; Tong, Gangling ; Li, Xiaoyu ; You, Danhui ; Cong, Minghua</creator><creatorcontrib>Li, Shuluan ; Wang, Tianyu ; Tong, Gangling ; Li, Xiaoyu ; You, Danhui ; Cong, Minghua</creatorcontrib><description>The effect of sarcopenia on the clinical outcomes of patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is unclear. The aim of this study was to evaluate the effect and survival of patients with malignancies and sarcopenia receiving ICIs. We systematically searched related studies in PubMed, Embase, and Cochrane Library up to March 2021 according to the inclusion and exclusion criteria. Information pertaining to the hazard ratio (HR) corresponding to 95% confidence interval (CI) of overall survival (OS) and progression-free survival (PFS) as determined by univariate and multivariate analyses; the odds ratio (OR) corresponding to the 95% CI of the disease control rate (DCR) and objective response rate (ORR); and immune-related adverse events (irAEs) was collected and analyzed using the RevMan 5.4 software. Study heterogeneity and sensitivity were also assessed. A total of 19 studies were finalized that included 1763patients with lung, gastrointestinal, and head and neck cancers as well as those with melanoma, renal cell carcinoma, urothelial carcinoma, pancreatic cancer, and soft tissue sarcoma. According to univariate and multivariate analyses, patients with sarcopenia at pre-immunotherapy had poorer PFS and OS than those without. HRs and the corresponding 95% CI of PFS were 1.91(1.55-2.34, p &lt;0.00001) and 1.46 (1.20-1.78, p =0.0001), respectively, and HRs and the corresponding 95% CI of OS were 1.78 (1.47-2.14, p &lt;0.00001) and 1.73 (1.36-2.19, p &lt;0.0001), respectively. Patients with sarcopenia showed poor PFS and OS during treatment. In addition, patients with sarcopenia had worse ORR (OR 0.46, 95% CI 0.28-0.74, p = 0.001) and DCR (OR 0.44, 95% CI 0.31-0.64, p&lt;0.0001); however, the incidence of irAEs of any grade and high-grade in patients with sarcopenia did not increase, OR and the corresponding 95% CI were 0.58(0.30-1.12, p = 0.10) and 0.46(0.19-1.09, p = 0.08). Further, we performed subgroup analysis, skeletal muscle mass index (SMI) and psoas muscle mass index (PMI) stratification. In the SMI group, patients with sarcopenia had poor ORR, DCR, PFS, and OS than those without. In the PMI group, sarcopenia had poor ORR,DCR, and was a poor prognostic factor for PFS and OS according to univariate analysis but had no effect on PFS and OS according to multivariate analysis. Patients with malignancies and sarcopenia at pre-immunotherapy or follow-up visits had poorer clinical outcomes than those without, and sarcopenia was a poor predictive factor of ICI immunotherapy outcomes.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2021.726257</identifier><identifier>PMID: 34513704</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>immunotherapy ; malignancies ; meta-analysis ; Oncology ; predictive factor ; sarcopenia</subject><ispartof>Frontiers in oncology, 2021-08, Vol.11, p.726257-726257</ispartof><rights>Copyright © 2021 Li, Wang, Tong, Li, You and Cong.</rights><rights>Copyright © 2021 Li, Wang, Tong, Li, You and Cong 2021 Li, Wang, Tong, Li, You and Cong</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3</citedby><cites>FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427761/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427761/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34513704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Shuluan</creatorcontrib><creatorcontrib>Wang, Tianyu</creatorcontrib><creatorcontrib>Tong, Gangling</creatorcontrib><creatorcontrib>Li, Xiaoyu</creatorcontrib><creatorcontrib>You, Danhui</creatorcontrib><creatorcontrib>Cong, Minghua</creatorcontrib><title>Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>The effect of sarcopenia on the clinical outcomes of patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is unclear. The aim of this study was to evaluate the effect and survival of patients with malignancies and sarcopenia receiving ICIs. We systematically searched related studies in PubMed, Embase, and Cochrane Library up to March 2021 according to the inclusion and exclusion criteria. Information pertaining to the hazard ratio (HR) corresponding to 95% confidence interval (CI) of overall survival (OS) and progression-free survival (PFS) as determined by univariate and multivariate analyses; the odds ratio (OR) corresponding to the 95% CI of the disease control rate (DCR) and objective response rate (ORR); and immune-related adverse events (irAEs) was collected and analyzed using the RevMan 5.4 software. Study heterogeneity and sensitivity were also assessed. A total of 19 studies were finalized that included 1763patients with lung, gastrointestinal, and head and neck cancers as well as those with melanoma, renal cell carcinoma, urothelial carcinoma, pancreatic cancer, and soft tissue sarcoma. According to univariate and multivariate analyses, patients with sarcopenia at pre-immunotherapy had poorer PFS and OS than those without. HRs and the corresponding 95% CI of PFS were 1.91(1.55-2.34, p &lt;0.00001) and 1.46 (1.20-1.78, p =0.0001), respectively, and HRs and the corresponding 95% CI of OS were 1.78 (1.47-2.14, p &lt;0.00001) and 1.73 (1.36-2.19, p &lt;0.0001), respectively. Patients with sarcopenia showed poor PFS and OS during treatment. In addition, patients with sarcopenia had worse ORR (OR 0.46, 95% CI 0.28-0.74, p = 0.001) and DCR (OR 0.44, 95% CI 0.31-0.64, p&lt;0.0001); however, the incidence of irAEs of any grade and high-grade in patients with sarcopenia did not increase, OR and the corresponding 95% CI were 0.58(0.30-1.12, p = 0.10) and 0.46(0.19-1.09, p = 0.08). Further, we performed subgroup analysis, skeletal muscle mass index (SMI) and psoas muscle mass index (PMI) stratification. In the SMI group, patients with sarcopenia had poor ORR, DCR, PFS, and OS than those without. In the PMI group, sarcopenia had poor ORR,DCR, and was a poor prognostic factor for PFS and OS according to univariate analysis but had no effect on PFS and OS according to multivariate analysis. Patients with malignancies and sarcopenia at pre-immunotherapy or follow-up visits had poorer clinical outcomes than those without, and sarcopenia was a poor predictive factor of ICI immunotherapy outcomes.</description><subject>immunotherapy</subject><subject>malignancies</subject><subject>meta-analysis</subject><subject>Oncology</subject><subject>predictive factor</subject><subject>sarcopenia</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkktv1DAQgCMEolXpnRPykUu2fm2S5YC0WgFdqVURLYKbNXHGuy6JndpO0f4Q_i9etlStL37MzDcj-SuKt4zOhGgWZ8Y7PeOUs1nNKz6vXxTHnAtZLqT4-fLJ-ag4jfGW5lXNKaPidXEk5JyJmsrj4s_X4DfOx2Q1WQ8j6ES8IdcQtB_RWSDekVVvndXQk6spaT9gJNaRS-jtxoHTNt9vAkLCjvywaZsxw-SQrLaof43eukTWbmtbm3yIH8iSXO9iwgH2Hb_hvcXfBFxHLjFBuXTQ76KNb4pXBvqIpw_7SfH986eb1Xl5cfVlvVpelFpWPJWSdwg1b7RspJEtdnU7r0SlBXbYGAFVwxFojlVoQDSmoYaB6JgxvBMN0-KkWB-4nYdbNQY7QNgpD1b9e_BhoyDkQXtUUrSGLupO0oZKyQAWUAEiwsJQAVpm1scDa5zaATuNLgXon0GfR5zdqo2_V43kdV2xDHj_AAj-bsKY1GCjxr4Hh36KKn8x54zVrM6p9JCqg48xoHlsw6jay6H2cqi9HOogRy5593S8x4L_Koi_IDu6IQ</recordid><startdate>20210826</startdate><enddate>20210826</enddate><creator>Li, Shuluan</creator><creator>Wang, Tianyu</creator><creator>Tong, Gangling</creator><creator>Li, Xiaoyu</creator><creator>You, Danhui</creator><creator>Cong, Minghua</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210826</creationdate><title>Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis</title><author>Li, Shuluan ; Wang, Tianyu ; Tong, Gangling ; Li, Xiaoyu ; You, Danhui ; Cong, Minghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>immunotherapy</topic><topic>malignancies</topic><topic>meta-analysis</topic><topic>Oncology</topic><topic>predictive factor</topic><topic>sarcopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Shuluan</creatorcontrib><creatorcontrib>Wang, Tianyu</creatorcontrib><creatorcontrib>Tong, Gangling</creatorcontrib><creatorcontrib>Li, Xiaoyu</creatorcontrib><creatorcontrib>You, Danhui</creatorcontrib><creatorcontrib>Cong, Minghua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Shuluan</au><au>Wang, Tianyu</au><au>Tong, Gangling</au><au>Li, Xiaoyu</au><au>You, Danhui</au><au>Cong, Minghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2021-08-26</date><risdate>2021</risdate><volume>11</volume><spage>726257</spage><epage>726257</epage><pages>726257-726257</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>The effect of sarcopenia on the clinical outcomes of patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is unclear. The aim of this study was to evaluate the effect and survival of patients with malignancies and sarcopenia receiving ICIs. We systematically searched related studies in PubMed, Embase, and Cochrane Library up to March 2021 according to the inclusion and exclusion criteria. Information pertaining to the hazard ratio (HR) corresponding to 95% confidence interval (CI) of overall survival (OS) and progression-free survival (PFS) as determined by univariate and multivariate analyses; the odds ratio (OR) corresponding to the 95% CI of the disease control rate (DCR) and objective response rate (ORR); and immune-related adverse events (irAEs) was collected and analyzed using the RevMan 5.4 software. Study heterogeneity and sensitivity were also assessed. A total of 19 studies were finalized that included 1763patients with lung, gastrointestinal, and head and neck cancers as well as those with melanoma, renal cell carcinoma, urothelial carcinoma, pancreatic cancer, and soft tissue sarcoma. According to univariate and multivariate analyses, patients with sarcopenia at pre-immunotherapy had poorer PFS and OS than those without. HRs and the corresponding 95% CI of PFS were 1.91(1.55-2.34, p &lt;0.00001) and 1.46 (1.20-1.78, p =0.0001), respectively, and HRs and the corresponding 95% CI of OS were 1.78 (1.47-2.14, p &lt;0.00001) and 1.73 (1.36-2.19, p &lt;0.0001), respectively. Patients with sarcopenia showed poor PFS and OS during treatment. In addition, patients with sarcopenia had worse ORR (OR 0.46, 95% CI 0.28-0.74, p = 0.001) and DCR (OR 0.44, 95% CI 0.31-0.64, p&lt;0.0001); however, the incidence of irAEs of any grade and high-grade in patients with sarcopenia did not increase, OR and the corresponding 95% CI were 0.58(0.30-1.12, p = 0.10) and 0.46(0.19-1.09, p = 0.08). Further, we performed subgroup analysis, skeletal muscle mass index (SMI) and psoas muscle mass index (PMI) stratification. In the SMI group, patients with sarcopenia had poor ORR, DCR, PFS, and OS than those without. In the PMI group, sarcopenia had poor ORR,DCR, and was a poor prognostic factor for PFS and OS according to univariate analysis but had no effect on PFS and OS according to multivariate analysis. Patients with malignancies and sarcopenia at pre-immunotherapy or follow-up visits had poorer clinical outcomes than those without, and sarcopenia was a poor predictive factor of ICI immunotherapy outcomes.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34513704</pmid><doi>10.3389/fonc.2021.726257</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2021-08, Vol.11, p.726257-726257
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_43bf097d4080441aa9a6aeeea9f03ac4
source PubMed Central (Open Access)
subjects immunotherapy
malignancies
meta-analysis
Oncology
predictive factor
sarcopenia
title Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A31%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Impact%20of%20Sarcopenia%20on%20Clinical%20Outcomes%20in%20Malignancies%20Treated%20With%20Immune%20Checkpoint%20Inhibitors:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Frontiers%20in%20oncology&rft.au=Li,%20Shuluan&rft.date=2021-08-26&rft.volume=11&rft.spage=726257&rft.epage=726257&rft.pages=726257-726257&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2021.726257&rft_dat=%3Cproquest_doaj_%3E2572211717%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-42dea728c484f4bed7b5636c3ede8f3a682ea084f6efa38f80f1a3d1ff2d381c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2572211717&rft_id=info:pmid/34513704&rfr_iscdi=true